The Effect of Auditory Interventions on Anxiety and Agitation in People With Dementia
1 other identifier
interventional
48
1 country
1
Brief Summary
The greying of the world is leading to a rapid acceleration in both the healthcare costs and caregiver burden that are associated with dementia. There is an urgent need to develop new, easily scalable modalities of support to reduce agitation and anxiety in those with dementia. There is evidence that music interventions reduce agitation and anxiety in those with dementia. LUCID has developed a novel digital music therapeutic product that uses a reinforcement learning AI agent to curate and personalize the musical playlist while incorporating binaural theta auditory beat stimulation (ABS) to reduce anxiety and agitation in those with dementia. This study will be conducted remotely with study hardware (tablets and Bluetooth speakers) being shipped to caregivers/participants' homes. The study will take place over a 2-week period, with participants completing 4 one-hour sessions per week along with an additional 1-hour follow-up interview session. Forty-eight participants with mild to moderate dementia (as defined by the Montreal Cognitive Assessment) will be evenly randomized to one of two conditions. The control condition consists of a selection of 30-minute audiobooks which the participant has the freedom to select from. The experimental condition consists of music and binaural ABS curated by LUCID's AI system. Participants' caregivers will complete baseline questionnaires assessing the participants' anxiety, agitation, and mood. They will also complete these questionnaires before and after each experimental session. The investigators hypothesize that the LUCID AI music curation system will have a greater agitation and anxiety reduction compared to the audiobook control condition.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 10, 2023
CompletedFirst Posted
Study publicly available on registry
May 6, 2023
CompletedStudy Start
First participant enrolled
May 8, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 2, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 3, 2023
CompletedNovember 22, 2023
May 1, 2023
3 months
April 10, 2023
November 21, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Cohen Mansfield Agitation Index
The purpose of this scale is to assess the frequency of manifestations of agitated behaviors in elderly persons. Minimum score: 14, Maximum score: 70. Higher score indicates a worse outcome (increased agitation).
2 weeks
Secondary Outcomes (6)
Rating of Anxiety in Dementia
2 weeks
Cornell Brown Scale for Quality of Life in Dementia
2 weeks
Zarit Caregiver Burden Interview
2 weeks
Positive and Negative Affect Scale
30 minutes
Overt Agitation Severity Scale
30 minutes
- +1 more secondary outcomes
Study Arms (2)
Music and Theta Auditory Beat Stimulation (ABS)
EXPERIMENTALParticipants listen to 30 minutes of personalized music with theta auditory beat stimulation (ABS).
Audiobooks
ACTIVE COMPARATORParticipants listen to a 30-minute audiobook.
Interventions
Listening to music and ABS for 30 minutes.
Eligibility Criteria
You may qualify if:
- Mild to Moderate Dementia (mild: Montreal Cognitive Assessment (MOCA) scores (18-25); moderate: MOCA scores (10-17)))
You may not qualify if:
- Unmanaged hearing loss (defined as average pure-tone average threshold of 35 dB HL or greater without the use of hearing instruments or personal sound amplification product)
- Severe Tinnitus
- Hyperacusis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Lucid, Inc.lead
Study Sites (1)
LUCID Therapeutics
Toronto, Ontario, M5C 1K9, Canada
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Adiel Mallik, PhD
Lucid, Inc.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 10, 2023
First Posted
May 6, 2023
Study Start
May 8, 2023
Primary Completion
August 2, 2023
Study Completion
August 3, 2023
Last Updated
November 22, 2023
Record last verified: 2023-05